These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 19618716)

  • 1. [Progress in the research of amorphous pharmaceuticals].
    Ying J; Lü Y; Du GH
    Yao Xue Xue Bao; 2009 May; 44(5):443-8. PubMed ID: 19618716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmaceutical significance of amorphous materials].
    Antal I; Zelkó R
    Acta Pharm Hung; 2008; 78(3):121-33. PubMed ID: 18986089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy.
    Heinz A; Strachan CJ; Gordon KC; Rades T
    J Pharm Pharmacol; 2009 Aug; 61(8):971-88. PubMed ID: 19703341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solid state amorphization of pharmaceuticals.
    Willart JF; Descamps M
    Mol Pharm; 2008; 5(6):905-20. PubMed ID: 18954076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N; de Matas M; Gavan PT; York P
    Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of particle size and preparation methods on the physical and chemical stability of amorphous simvastatin.
    Zhang F; Aaltonen J; Tian F; Saville DJ; Rades T
    Eur J Pharm Biopharm; 2009 Jan; 71(1):64-70. PubMed ID: 18703139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing early formulations: practice and perspective.
    Li P; Zhao L
    Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of calcined Mg-Al-hydrotalcite to enhance the stability of celecoxib in the amorphous form.
    Ambrogi V; Perioli L; Marmottini F; Rossi C
    Eur J Pharm Biopharm; 2007 May; 66(2):253-9. PubMed ID: 17123798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging trends in the stabilization of amorphous drugs.
    Laitinen R; Löbmann K; Strachan CJ; Grohganz H; Rades T
    Int J Pharm; 2013 Aug; 453(1):65-79. PubMed ID: 22569230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amorphous solid dispersions: a robust platform to address bioavailability challenges.
    Newman A; Nagapudi K; Wenslow R
    Ther Deliv; 2015 Feb; 6(2):247-61. PubMed ID: 25690090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaches for the development of solid and semi-solid lipid-based formulations.
    Jannin V; Musakhanian J; Marchaud D
    Adv Drug Deliv Rev; 2008 Mar; 60(6):734-46. PubMed ID: 18045728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of cyclodextrins for enhancing oral bioavailability.
    Carrier RL; Miller LA; Ahmed I
    J Control Release; 2007 Nov; 123(2):78-99. PubMed ID: 17888540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An investigation into the influence of counterion on the properties of some amorphous organic salts.
    Towler CS; Li T; Wikström H; Remick DM; Sanchez-Felix MV; Taylor LS
    Mol Pharm; 2008; 5(6):946-55. PubMed ID: 19434850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supercritical fluid technologies: an innovative approach for manipulating the solid-state of pharmaceuticals.
    Pasquali I; Bettini R; Giordano F
    Adv Drug Deliv Rev; 2008 Feb; 60(3):399-410. PubMed ID: 17964684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solubility advantage of amorphous pharmaceuticals, part 3: Is maximum solubility advantage experimentally attainable and sustainable?
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    J Pharm Sci; 2011 Oct; 100(10):4349-56. PubMed ID: 21630280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Crystalline modifications and polymorphism changes during drug manufacture].
    Doelker E
    Ann Pharm Fr; 2002 May; 60(3):161-76. PubMed ID: 12050595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Amorphization in pharmaceutical technology].
    Révész P; Laczkovich O; Eros I
    Acta Pharm Hung; 2004; 74(1):39-44. PubMed ID: 15524047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of cocrystals in pharmaceutical science.
    Shan N; Zaworotko MJ
    Drug Discov Today; 2008 May; 13(9-10):440-6. PubMed ID: 18468562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A; Hoffman A
    J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.